ClinicalTrials.gg
Drug

Favipiravir clinical trials

Also written Avigan and T-705.

studies test it
58
open now
7
in phase 3
23
first study started
2010

How each study uses favipiravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the favipiravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Favipiravir
45
AVIGAN 200 mg FT
3
AVIGAN 200 MG Film Tablets
3
Areplivir
2

Brand

Avigan
10

Development codes

T-705
5

Studies by the year they started

58 studies that test it; most in 2020 (37)

Studies that test favipiravir, by start year
YearStudies
20101
20111
20121
20131
20143
20161
20181
202037
20216
20221
20231
20242
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
10
Phase 2
27
Phase 3
23
Phase 4
2
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 19 · Other 39

MDVI, LLC (5) · Institut National de la Santé Et de la Recherche Médicale, France (3) · University of Oxford (3) · Appili Therapeutics Inc. (2) · Promomed, LLC (2) · King Abdullah International Medical Research Center (2) · Peking University First Hospital (2) · Shin Poong Pharmaceutical Co. Ltd. (1)

Often tested with

Tested in the same studies.

Hydroxychloroquine (5) · Molnupiravir (4) · Nitazoxanide (3) · Remdesivir (2) · Nirmatrelvir and ritonavir drug combination (2) · Ribavirin (2) · Artesunate (1) · Amodiaquine (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6, 1 in phase 3

Studies that test favipiravir, phase 3 first.

Studies

Open first, then newest update. How each study uses favipiravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 58

See all 58 studies that test favipiravir →

Given beside what is tested · 5 — favipiravir is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with favipiravir

Codes

What other systems call favipiravir · ClinicalTrials.gg INT004464

  • MeSH (NLM) C462182favipiravirConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) EW5GL2X7E0FAVIPIRAVIRConfirmed FDA, NLM, Wikidata
  • Wikidata Q16934561favipiravirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C81605FavipiravirOne source FDA
  • DrugBank DB12466One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.